New pill aims to keep heart in rhythm after AFib episode

NCT ID NCT06540352

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a new drug called Refralon, taken as a tablet once or twice daily, can prevent atrial fibrillation or flutter from returning after normal heart rhythm has been restored. About 175 adults with persistent AFib will receive either Refralon or a placebo for 6 months. Researchers will check heart rhythm at several points to see if the drug helps maintain normal rhythm better than a dummy pill.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Refralon (a drug in tablet form)
What this could lead to
If successful, this could provide a new oral medication to help people with persistent atrial fibrillation stay in normal heart rhythm and avoid repeat episodes.
What could go wrong
This is an early phase 2 study with only 175 people, so results may not apply broadly. The drug may not work better than placebo, and side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Medical Research Center for Cardiology, Ministry of Health of Russian Federation Organization

    Moscow, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.